<DOC>
	<DOCNO>NCT01229085</DOCNO>
	<brief_summary>To evaluate efficacy combination mometasone furoate 0.1 % Salicylic Acid 5 % patient sex present clinical symptom psoriasis mild moderate .</brief_summary>
	<brief_title>Efficacy Study Combination Mometasone + Salicylic Acid Patients With Psoriasis</brief_title>
	<detailed_description>Phase III clinical trial , systematic sampling , open-label study evaluate efficacy combination mometasone furoate 0.1 % 5 % salicylic acid 71 patient lesion mild moderate psoriasis treat 45 day less , discretion investigator . The result statistically analyzed investigational data conclusion refer report .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<criteria>Adults sex , regardless color social class ; Age 18 old , good mental health ; Psoriasis patient mild moderate ; Patients agree participate sign Clarified ( appendix ) ; Patients agree return followup visit . Patients make use biologics , corticosteroid nonsteroidal antiinflammatory nonsteroid , make use topical medication 15 day inclusion 30 day inclusion administration orally ; Patients expose sun 15 day study begin course ; Patients make use acetaminophen ; Patients agree term describe IC informed consent , Patients also psoriatic plaque skin disorder cause fungi bacteria make use antibiotic antifungal ; Lions type skin damage psoriasis ; Pregnant nursing woman ; Patients use oral anticoagulant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Psoriasis , mometasone , salicylic acid .</keyword>
</DOC>